Niagen Bioscience (NAGE) Receivables - Other (2013 - 2026)
Niagen Bioscience (NAGE) posted quarterly Receivables - Other of $3.4 million for Q1 2026, up 267.5% year-over-year from $928432.3 in Q1 2025, and up 170.36% quarter-over-quarter from $1.3 million in Q4 2025.
Niagen Bioscience (NAGE) Receivables - Other (2013 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Receivables - Other for 11 consecutive years, with $3.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Other rose 267.5% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $6.2 million (up 386.87% YoY), while the FY2025 annual figure was $756000.0, down 40.89% from the prior year.
- Receivables - Other improved to $3.4 million in Q1 2026 per NAGE's latest filing, from $1.3 million in the prior quarter.
- Across five years, Receivables - Other topped out at $3.8 million in Q4 2022 and bottomed at -$2.7 million in Q2 2023.
- Historically, Receivables - Other has averaged $904764.7 across 5 years, with a median of $1.3 million in 2025.
- Annual changes were most pronounced in 2022 — Receivables - Other surged 2802.31% — and 2023, when it sank 305.23%.
- Niagen Bioscience's Receivables - Other stood at $3.8 million in 2022, then slumped by 109.22% to -$348000.0 in 2023, then slumped by 84.48% to -$642000.0 in 2024, then surged by 296.57% to $1.3 million in 2025, then jumped by 170.36% to $3.4 million in 2026.
- Business Quant data shows NAGE's Receivables - Other at $3.4 million in Q1 2026, $1.3 million in Q4 2025, and -$1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.55 Mn |
| Jun 30, 2026 | -4.55 Mn |
| Mar 31, 2026 | 3.41 Mn |
| Mar 31, 2026 | 3.41 Mn |
| Dec 31, 2025 | 1.26 Mn |
| Dec 31, 2025 | 1.26 Mn |
| Sep 30, 2025 | -1.16 Mn |
| Sep 30, 2025 | -1.16 Mn |
| Jun 30, 2025 | 2.69 Mn |
| Jun 30, 2025 | 2.69 Mn |
| Mar 31, 2025 | -2.04 Mn |
| Mar 31, 2025 | -2.04 Mn |
| Dec 31, 2024 | -642,000.00 |
| Dec 31, 2024 | -642,000.00 |
| Sep 30, 2024 | -710,000.00 |
| Sep 30, 2024 | -710,000.00 |
| Jun 30, 2024 | 1.23 Mn |
| Jun 30, 2024 | 1.23 Mn |
| Mar 31, 2024 | 1.41 Mn |
| Mar 31, 2024 | 1.41 Mn |